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Figure E1.  Daily grass pollen counts for North London in 2009  
 
All nasal allergen challenges were completed in the study between January and late April  
2009. It was found that grass pollen counts of >30 grains/m3 were only present after late May, 
2009. Please note that the date format is month/day/year. This data is courtesy of Dr. Jean 
Emberlin, former Director of the National Pollen and Aerobiology Research Unit, Worcester.   
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Figure E2. Total nasal symptom scores (TNSS) after nasal allergen challenge (NAC) 
 
“Non-Responders” (n=8) and “Responders” (n=11) are defined on the basis of their IL-13 levels 
in nasal MLF at 2-8h post NAC (see text). Blue = placebo followed by NAC, Orange = 10mg 
prednisone followed by NAC, Red = 25mg prednisone followed by NAC 
  
Following NAC participants had early (within the first hour) nasal symptoms: generally 
consisting of sneezing for a few minutes with rhinorrhea and nasal and soft palate itching for up 
to 30 mins, that largely resolved within an hour. Symptoms are subjective in rhinitis, especially 
during the late phase (2-8h post NAC), that consists largely of a slight nasal obstruction. Some 
AR patients had an early symptomatic response with little or no late symptomatic response. 
TNSS are displayed as means over time, graded 0 to 3 for nasal itch, nasal obstruction, nasal 
discharge and sneezing: this corresponds to a maximal TNSS of 12. TNSS in the late phase are 
variable and of low magnitude: reaching only mean levels of around 2 out of 12, and largely due 
to obstruction alone. 
 
There were trends for increased early (1h) and late (2-8h) TNSS in the Responder group, when 
compared to the Non-Responder group (these did not reach statistical significance).  
In the responder group area under the curve (AUC) analysis showed a trend for decreased 
TNSS levels following prednisone administration, relative to placebo. 
A  All subjects B  Responders C  Non- Responders 
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Figure E3. Total nasal symptom scores (TNSS) after nasal allergen challenge (NAC) 
 
A. TNSS scores over time (at each hour in the late phase) in Responders (green) versus Non-
Responders (purple), in the placebo followed by NAC arm, shown as means and SEM. 
At all timepoints after NAC there is a trend for reduced TNSS in Non-Responders. 
 
B. TNSS scores (means) in the late phase (2-8h) in Responders (green) versus Non-
Responders (purple), showing a trend for greater TNSS in the Responder group that did not 
achieve statistical significance. On the right we see that and there were approximately double 
the mean levels of TNSS evaluated by AUC 2-8h in the Responder versus Non-Responder 
group.  
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Figure E4. Individual total nasal symptom scores (TNSS) after nasal allergen challenge 
(NAC) 
 
“Non-Responders” (n=8) and “Responders” (n=11) are defined on the basis of their IL-13 levels 
in nasal MLF (see text).  
 
Blue = placebo followed by NAC 
Orange = 10mg prednisone followed by NAC 
Red = 25mg prednisone followed by NAC 
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Figure E5.  Time courses of geometric mean absolute cytokine levels in MLF following 
nasal allergen challenge  
 
Levels of cytokines and CCL4 were measured by immunoassay in eluted nasosorption samples. 
In all panels, blue denotes placebo pretreatment, orange denotes 10mg prednisone 
pretreatment, and red denotes 25mg prednisone pretreatment.  
 
A B 
C D 
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Figure E6.  Time courses of individual IL-5 responses to NAC   
Blue denotes placebo pretreatment, orange denotes 10mg prednisone pretreatment, and red 
denotes 25mg prednisone pretreatment.   
“R” denotes IL-13 Responder status as explained in the main text. There are 18 subjects, with 
subject 19R having insufficient sample for IL-5 measurement, but included in Fig 2C in the main 
manuscript. 
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Figure E7.  Unsupervised hierarchical clustering heatmap of NAC-induced gene 
expression changes with probesets as columns and study participants as rows  
Color coded values are fold changes (log10) of 8h post-NAC probeset expression compared with 
common study baseline (Figure 1).  Participants are listed by study allocation number (“AN”) 
and by nasal cytokine IL-13 Responder status (“R” or “NR”) as defined in the manuscript. 
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Figure E8.  Principal components analysis (PCA) of changes in probeset expression 
levels following NAC (placebo pretreatment) 
Left panel: Fraction of total gene expression variance explained by the first 10 principal 
components. 
Right panel: Principal component coefficients of subjects in the two dimensional space made up 
of principal components 1 and 2.  Each cross symbol corresponds to a patient – identified with 
an adjacent allocation number: green squares correspond to IL-13 Responders and purple 
crosses correspond to Non-Responders.   
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Figure E9. Correlation matrix and dendrogram for key parameters of the nasal allergen 
challenge (NAC)  
 
Correlation Matrix (left) in which the magnitude of Pearson correlation (“r”) is reflected in colour 
(see scale bar) and also by the diameter of circles. Analysis was carried out on data from the 
placebo period, thus reflecting NAC biology in the absence of any treatment. This illustrates 
correlations between total nasal symptom scores (TNSS) in the late phase (2-8h) after NAC, IL-
33 mRNA at baseline, the first transcriptional principal component (PCA1, Figure E8) across the 
allergen gene expression signature,  post-NAC change from baseline in several immunologically 
relevant mRNAs including neutrophil and eosinophil mRNA-derived markers; and selected 
cytokine and chemokine protein levels (IL-5, IL-13, IL-1β and CCL4/MIP-1β: geometric mean 
time weighted average, GMTWA, 2-8hr).   
Nomenclature for chemokines: CCL2/MCP-1, CCL4/MIP-1β, CCL13/MCP-4, CCL23/MIP-3, 
CCL26/eotaxin-3. IL-33 gene expression is at baseline. 
“Responders” were based on IL-13 protein levels after NAC, assessed by geometric mean time 
weighted averages (GMTWA) at 2-8h post placebo NAC (see manuscript for definition).  
 
Dendrogram (right) of hierarchical clustering, showing correlation distances and average link. 
The eosinophil mRNA derived marker is clustered with gene expression (change from baseline) 
for type 2 inflammation. The neutrophil gene signature is clustered with oncostatin M (OSM), IL-
1B, IL-8, IL-1A gene expression. IL-33 baseline gene expression clusters with IL-5, IL-13, 
CCL4/MIP-1β and IL-1β protein levels (GMTWA, 2-8h): and therefore with IL-13 Responders. 
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Figure E10. Comparison of “IL-13 Responders” and Non-Responders with regard to 
responses after nasal allergen challenge (NAC) 
 
Post hoc stratification of IL-13 protein Responders  after NAC is reflected in key endpoints. Post 
NAC (preceded by placebo) across key endpoints. Selected proteins: IL-5, IL-13, IL-1β and 
CCL4/MIP-1β (pg/ml) (geometric mean time weighted average, log10 transformed (GMTWA, 2-
8hr). TNSS: total nasal symptom scores in the late phase (2-8h). PCA1: first principal 
components analysis across the NAC gene expression signature (change from baseline). 
mRNA genes and neutrophil and eosinophil mRNA derived markers (change from baseline, 
log10 transformed). IL-33 gene expression is shown at baseline. P-values in this situation 
should be interpreted with caution, as these are nominal, not adjusted for multiplicity and 
performed post hoc. 
 
Endpoint p-value 
IL-5 protein Used for 
Responder 
stratification 
IL-13 protein 
IL-1β protein 1.74E-02 
MIP-1β protein 2.00E-03 
TNSS (2-8h) 1.79E-01 
PCA1 1.00E-04 
IL-33 baseline 1.65E-02 
CD69 1.16E-03 
eosinophil 7.93E-03 
CCL23 1.84E-02 
IL-5 2.49E-01 
IL-13 2.61E-01 
neutrophil 1.31E-01 
IL-8 7.03E-02 
IL-1β 5.29E-02 
OSM 1.37E-01 
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Figure E11. Pearson correlation between total nasal symptom scores TNSS (2-8hr) and 
key gene expression and cytokine levels after nasal allergen challenge (NAC) 
 
IL-13 Responders (defined in the manuscript, green dots) and Non-Responders (purple dots) 
are shown. This confirms that TNSS in the late phase (2-8hr) are not associated with changes 
from baseline in levels of IL-5 and IL-13. The correlation of TNSS with IL-31 is weak and based 
mainly on a single point, and has not been corrected for multiple testing. Values for mRNA and 
proteins are log10 transformed NAC fold change from baseline. 
Endpoint Correlation P-value 
IL-31mRNA 0.530 0.029 
IL-9mRNA 0.384 0.129 
IL-5mRNA 0.175 0.501 
PCA1 0.164 0.530 
IL-5 and IL-13 protein Used for Responder stratification 
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Table E1. Baseline demographics 
 
 
 
 
Participant number 
 Age_(yr) Sex Race category 
Baseline blood 
eosinophil count 
(thousands/L) 
1  41 M white 0.11 
2  35 F white 0.13 
3 52 M white 0.24 
4 36 M black 0.17 
5 49 M white 0.07 
6 46 M white 0.18 
7 29 M white 0.14 
8  55 M white 0.04 
9 44 M white 0.08 
10  39 M black 0.38 
11 36 M white 0.07 
12 53 F black 0.05 
13 47 M white 0.38 
14  38 M white 0.85 
15  33 M white 0.07 
16  51 M white 0.09 
17 29 M white 0.31 
18  32 M white 0.08 
19  22 M Asian 0.17 
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Table E2.  Geometric mean time weighted average (hours 2-8) fold differences from 
baseline in allergen-induced inflammatory markers, as measured in MLF: Treatment 
group comparisons 
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Table E3.  Geometric mean fold differences from baseline at hour 7 in allergen-induced 
inflammatory markers, as measured in MLF: Treatment group comparisons 
 
 
Analyte    Treatment Group     GM    90% CI    1-sided  Effect Size 
    Comparison     FD    for GM FD    P-value  (log scale) 
IL-5     10 mg prednisone vs. Placebo              0.32 ( 0.14,  0.71)  0.011  -0.806 
         25 mg prednisone vs. Placebo              0.11 ( 0.05,  0.24) <0.001  -1.579 
         25 mg prednisone vs. 10 mg prednisone     0.34 ( 0.15,  0.74)  0.013  -0.774 
IL-13    10 mg prednisone vs. Placebo              0.41 ( 0.22,  0.76)  0.010  -0.798 
         25 mg prednisone vs. Placebo              0.14 ( 0.08,  0.26) <0.001  -1.748 
         25 mg prednisone vs. 10 mg prednisone     0.34 ( 0.19,  0.64)  0.003  -0.950 
MIP-1      10 mg prednisone vs. Placebo              0.75 ( 0.41,  1.37)  0.211         
         25 mg prednisone vs. Placebo              0.35 ( 0.19,  0.65)  0.003  -0.971 
         25 mg prednisone vs. 10 mg prednisone     0.47 ( 0.26,  0.87)  0.022  -0.700 
ENA-78   10 mg prednisone vs. Placebo              1.01 ( 0.41,  2.49)  0.508         
         25 mg prednisone vs. Placebo              0.95 ( 0.39,  2.31)  0.463         
         25 mg prednisone vs. 10 mg prednisone     0.94 ( 0.38,  2.32)  0.456         
MCP-1    10 mg prednisone vs. Placebo              0.97 ( 0.49,  1.94)  0.474         
         25 mg prednisone vs. Placebo              0.65 ( 0.33,  1.30)  0.152         
         25 mg prednisone vs. 10 mg prednisone     0.67 ( 0.34,  1.34)  0.168         
IL-6     10 mg prednisone vs. Placebo              1.32 ( 0.83,  2.09)  0.840         
         25 mg prednisone vs. Placebo              0.69 ( 0.43,  1.09)  0.089         
         25 mg prednisone vs. 10 mg prednisone     0.52 ( 0.33,  0.83)  0.011  -0.797 
MIP-1  10 mg prednisone vs. Placebo              0.92 ( 0.80,  1.05)  0.148         
         25 mg prednisone vs. Placebo              0.87 ( 0.76,  1.00)  0.049  -0.567 
         25 mg prednisone vs. 10 mg prednisone     0.95 ( 0.83,  1.09)  0.264         
IL-4     10 mg prednisone vs. Placebo              0.97 ( 0.93,  1.01)  0.115         
         25 mg prednisone vs. Placebo              0.97 ( 0.93,  1.01)  0.115         
         25 mg prednisone vs. 10 mg prednisone     1.00 ( 0.96,  1.05)  0.500         
RANTES   10 mg prednisone vs. Placebo              1.05 ( 0.87,  1.26)  0.669         
         25 mg prednisone vs. Placebo              1.20 ( 0.99,  1.44)  0.944         
         25 mg prednisone vs. 10 mg prednisone     1.14 ( 0.95,  1.37)  0.879         
IL-1         10 mg prednisone vs. Placebo              0.58 ( 0.32,  1.04)  0.062         
         25 mg prednisone vs. Placebo              0.39 ( 0.22,  0.71)  0.005  -0.900 
         25 mg prednisone vs. 10 mg prednisone     0.68 ( 0.38,  1.22)  0.135         
IL-8     10 mg prednisone vs. Placebo              1.34 ( 0.77,  2.34)  0.811         
         25 mg prednisone vs. Placebo              0.93 ( 0.53,  1.63)  0.417         
         25 mg prednisone vs. 10 mg prednisone     0.70 ( 0.40,  1.21)  0.139         
GM FD = Geometric Mean Fold Difference, CI = Confidence Interval 
Effect sizes shown on log scale for statistically significant comparisons. 
Final Results, Date:  09/03/2009 
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Table E4.  Geometric mean fold differences from baseline at hour 8 in allergen-induced 
inflammatory markers, as measured in MLF: Treatment group comparisons 
 
Analyte    Treatment Group     GM    90% CI    1-sided  Effect Size 
    Comparison     FD    for GM FD    P-value  (log scale) 
IL-5    10 mg prednisone vs. Placebo              0.25 ( 0.12,  0.54)  0.002  -1.021 
         25 mg prednisone vs. Placebo              0.07 ( 0.03,  0.15) <0.001  -1.962 
         25 mg prednisone vs. 10 mg prednisone     0.28 ( 0.13,  0.60)  0.004  -0.941 
IL-13    10 mg prednisone vs. Placebo              0.32 ( 0.18,  0.56)  0.001  -1.106 
         25 mg prednisone vs. Placebo              0.12 ( 0.07,  0.22) <0.001  -2.021 
         25 mg prednisone vs. 10 mg prednisone     0.39 ( 0.22,  0.68)  0.004  -0.915 
MIP-1        10 mg prednisone vs. Placebo              0.66 ( 0.37,  1.18)  0.116         
         25 mg prednisone vs. Placebo              0.29 ( 0.16,  0.51) <0.001  -1.219 
         25 mg prednisone vs. 10 mg prednisone     0.44 ( 0.25,  0.78)  0.010  -0.813 
MCP-1    10 mg prednisone vs. Placebo              1.00 ( 0.55,  1.82)  0.496         
         25 mg prednisone vs. Placebo              0.63 ( 0.35,  1.15)  0.102         
         25 mg prednisone vs. 10 mg prednisone     0.63 ( 0.35,  1.15)  0.104         
IL-6     10 mg prednisone vs. Placebo              1.29 ( 0.77,  2.13)  0.797         
         25 mg prednisone vs. Placebo              0.65 ( 0.39,  1.08)  0.080         
         25 mg prednisone vs. 10 mg prednisone     0.51 ( 0.30,  0.84)  0.015  -0.760 
ENA-78   10 mg prednisone vs. Placebo              1.08 ( 0.43,  2.75)  0.556         
         25 mg prednisone vs. Placebo              1.08 ( 0.42,  2.73)  0.552         
         25 mg prednisone vs. 10 mg prednisone     0.99 ( 0.39,  2.53)  0.496         
IL-1         10 mg prednisone vs. Placebo              0.53 ( 0.31,  0.93)  0.033  -0.637 
         25 mg prednisone vs. Placebo              0.25 ( 0.14,  0.44) <0.001  -1.399 
         25 mg prednisone vs. 10 mg prednisone     0.47 ( 0.27,  0.82)  0.014  -0.762 
MIP-1   10 mg prednisone vs. Placebo              0.99 ( 0.91,  1.07)  0.401         
         25 mg prednisone vs. Placebo              0.92 ( 0.85,  1.00)  0.046  -0.575 
         25 mg prednisone vs. 10 mg prednisone     0.93 ( 0.86,  1.01)  0.074         
RANTES   10 mg prednisone vs. Placebo              1.09 ( 0.95,  1.25)  0.843         
         25 mg prednisone vs. Placebo              0.99 ( 0.87,  1.14)  0.473         
         25 mg prednisone vs. 10 mg prednisone     0.91 ( 0.80,  1.05)  0.142         
IL-8     10 mg prednisone vs. Placebo              1.32 ( 0.72,  2.41)  0.777         
         25 mg prednisone vs. Placebo              0.77 ( 0.42,  1.40)  0.232         
         25 mg prednisone vs. 10 mg prednisone     0.58 ( 0.32,  1.07)  0.070         
GM FD = Geometric Mean Fold Difference, CI = Confidence Interval 
Effect sizes shown on log scale for statistically significant comparisons. 
Final Results, Date:  09/03/2009 
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Table E5.  Gene transcripts included in prospectively defined mRNA derived markers of 
eosinophils, neutrophils, and mast cells  
 
Eosinophil-
associated 
Mast Cell-
Associated 
Neutrophil-Associated 
CLC   
SIGLEC8  
EMR1  
EMR4P   
LGALS12    
HRH4 
CEBPE 
DACH1 
VSTM1  
MS4A2   
TPSAB1   
TPSB2  
CPA3   
RGS13  
C1orf186  
FCGR2A  
FCGR2C 
CXCR1 
CXCR2 
FPR1   
MME 
GLT1D1  
TREM1 
SLC2A3  
SIRPB1 
DYSF  
MEFV 
IFITM2 
FOS 
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Table E6. Table of genes known to be genetic modifiers of asthma: association of 
baseline nasal gene expression (mRNA) with magnitude of the NAC response (IL-5 and 
IL-13 protein, change from baseline) 
 
Gene Probeset Transcript 
Correlation with  
IL-13 protein NAC  
Correlation with  
IL-5 protein NAC  
Pearson, 
r 
p-value 
Pearson, 
r 
p-value 
ADAMTS4 100127399_TGI_at NM_005099 -0.326 0.217 -0.376 0.167 
ADAMTS4 100302649_TGI_at NM_005099 -0.322 0.223 -0.391 0.149 
BACH2 100155509_TGI_at NM_021813 -0.207 0.442 -0.031 0.913 
CLEC16A 100149696_TGI_at NM_015226 0.315 0.235 0.288 0.298 
D2HGDH 100154978_TGI_at NM_152783 -0.044 0.872 0.035 0.901 
FCER1G 100160419_TGI_at NM_004106 0.024 0.93 -0.029 0.919 
GAPT 100125122_TGI_at NM_152687 -0.028 0.919 -0.077 0.785 
GATA3 100160989_TGI_at NM_001002295 0.234 0.384 0.042 0.881 
GATA3 100303528_TGI_at NM_001002295 0.227 0.397 0.064 0.821 
GSDMB 100144966_TGI_at NM_001042471 0.171 0.526 0.138 0.625 
IL33 100159118_TGI_at NM_033439 0.685 0.0034 0.808 0.0003 
LRP1 100302931_TGI_at NM_002332 0.256 0.338 0.377 0.166 
RAD50 100132153_TGI_at NM_133482 0.117 0.666 0.199 0.478 
SMAD3 100134075_TGI_at NM_005902 -0.199 0.459 -0.035 0.902 
STAT6 100156721_TGI_at NM_003153 0.077 0.777 -0.056 0.843 
 
Since these genetic drivers of asthma have been demonstrated to alter the risk of development 
of asthma, baseline expression level might affect the magnitude of the subsequent allergen 
response up to 12 weeks later. Only genetics findings with measurable expression at baseline 
were included in this correlation analysis. Within this list IL-33 mRNA at baseline is strongly 
associated with IL-5 and IL13 protein responses after NAC. These correlations remain 
statistically significant after Bonferroni correction for multiple hypothesis-testing. 
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Table E7. Baseline gene expression and prediction of IL-5/IL-13 protein responses after 
NAC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values represent the smallest Benjamini-Hochberg false discovery rate (FDR) (SAS Proc Mult 
Test procedure) observed across the whole array of the genome (52,369 probe sets) as 
observed in baseline prediction tests. MAS5 was present in 31,892 probe sets. Given the small 
sample size, we cannot identify a de novo gene signature with a reasonable FDR (i.e. <0.2) that 
would predict subsequent NAC Responders. The study sample size was based on the primary 
end-point (PEP), and was not powered to detect the baseline gene expression prediction signal 
for IL-13 Responders. 
Statistical test MAS5 present Whole array 
Responder ~ Baseline 1.000 1.000 
Baseline ~ Responder 1.000 1.000 
IL-5 protein ~ Baseline 0.666 0.716 
IL-13 protein ~ Baseline 1.000 1.000 
TNSS (2-8hr) ~ Baseline 1.000 1.000 
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Data File S1
 
Data File S1.  Expression patterns (aggregate amongst all subjects) of probesets regulated by 
allergen challenge and/or 25mg prednisone – with MAS5 present call in >50% of samples in a 
treatment group (placebo and/or 25mg prednisone), |fold change| >1.5, and FDR < 10%. 
 
Data File S2
 
Data File S2.  Expression patterns (amongst Responders only) of probesets regulated by 
allergen challenge (FDR <5%) used for Ingenuity analysis. 
 
Data File S3
 
Data File S3.  Data table of gene symbols and respective z-scores and FDR (< 0.05) of 
prednisone effects (prednisone vs. placebo pretreatment) used for Ingenuity Pathway Analysis. 
 
 
